about
The effects of psychostimulant drugs on blood brain barrier function and neuroinflammationOligodendrogenesis in the normal and pathological central nervous systemNo evidence for XMRV in German CFS and MS patients with fatigue despite the ability of the virus to infect human blood cells in vitroEfficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trialMultiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormoneMicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole bloodCutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic reviewChronic cerebro-spinal venous insufficiency (CCSVI) and multiple sclerosisDevelopment of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachAdverse effects of immunotherapies for multiple sclerosis: a network meta-analysisFingolimod for relapsing-remitting multiple sclerosisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisInterferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosisInformation provision for people with multiple sclerosisPercutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patientsPercutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patientsInterferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosisInformation provision for persons with multiple sclerosisFingolimod for relapsing remitting multiple sclerosisAcupuncture for multiple sclerosisTNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosisOral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trialHuman herpesvirus 6 infection as a trigger of multiple sclerosisAnti-acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune encephalomyelitis mouseGenetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisZinc in Multiple Sclerosis: A Systematic Review and Meta-AnalysismiRNAs Participate in MS Pathological Processes and Its Therapeutic ResponseDouble Roles of Macrophages in Human Neuroimmune Diseases and Their Animal ModelsThe role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studiesFatigue Management in Multiple SclerosisManagement of Multiple Sclerosis in the Breastfeeding MotherFocus on Extracellular Vesicles: Physiological Role and Signalling Properties of Extracellular Membrane VesiclesTh17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic ImplicationsB Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic InterventionsExploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosisRetinal Cell Degeneration in Animal ModelsFatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain StimulationInvolvement of CD8(+) T Cells in Multiple SclerosisHypersensitivity Responses in the Central Nervous System
P2860
Q21129283-8F6FB8ED-5645-4D9B-A4EC-46EC54695788Q21129352-AD6CE7BF-6C62-4686-98AD-6EED8AEEA35DQ21135591-7AF1BF8A-0FE1-437D-9C2E-104711103E43Q21203734-6137C8F3-73D0-493F-8B2C-9AE1D22D30C5Q21558407-30842175-696A-462F-9723-774403E240BEQ21562182-BD83F4AD-DCCA-4E29-86FB-9CE59B7B918BQ22241795-D59B58A0-3A4F-4E66-90BB-2606CD682D95Q22252683-C2709F57-6EAA-4FD4-9EE0-5331C9074C77Q22305854-67A66E4A-323B-4FED-8714-03E4F251BBC3Q24185820-7C983C71-6FC7-4B2B-AABE-82B6A946DB76Q24185882-86FD2BBD-67F2-4FA4-A7B3-A89F36777FC1Q24187126-FA974538-5AE1-4366-B6A5-6B4BA2E1194CQ24188270-EAEEF2E3-3C5F-42AB-B877-E8D3B1F74B97Q24194800-17054581-4F8E-442C-824A-9BC3B5F668C9Q24195040-B2CE88C1-4C0E-4F16-BADB-1C944E4EFE4AQ24202111-017EAAE2-FAEC-4E96-A952-C5538BF6ECACQ24202967-009985C7-BE5D-427B-A571-0DD8047F00F3Q24234763-F87CB774-295B-4D3E-9407-7B9AE9671720Q24235042-CD485CFB-4F85-4A90-94E5-C3854F07CF3FQ24236597-0E1EC7BE-71F6-4070-A78C-42BC0ECE8A7AQ24241139-AC47CF2A-9403-4981-ADEA-3008153A5B6AQ24293476-6C6A4DAD-D746-4294-AAF3-53B2030F31B2Q24564715-CE55645E-5C04-40D5-834B-94D76A7CF730Q24620734-3F2C9FAC-F655-4266-BEC5-19729EDF1EF5Q24630119-2514F987-3031-417A-9D40-8EC6B8F195BCQ24635370-233C0F2E-88D1-42FC-B9DC-B5941CFD4371Q26747289-BDC8EDC2-3F79-40AA-99B3-0F38BE1D52CEQ26748774-92F45064-6125-4880-B07C-839893AE06A4Q26749131-5FBAF3CD-3A2B-4D77-802E-4E285F45D473Q26750597-E700052C-C520-435E-A862-B139BFFD0E75Q26752946-5E601C9C-33D8-4C58-B5F6-2EC8D7E8B6F9Q26766337-55664262-FEC0-4DDF-B744-B7C1810CC6CAQ26767270-CCB3392B-6BD2-4BEF-B195-735F4B80F7B4Q26768649-1A619786-9BA6-41C6-BF2D-CB36922E0146Q26770664-75598C54-AD17-4468-A470-977376C35A12Q26770818-2907DF07-0C88-49FD-99DE-C36B2F0DB1B3Q26771160-CD831F05-87B9-427F-BE73-26442C2609D0Q26773166-312B8F8A-6D9D-46C8-AAA8-DBC63DF813C2Q26774642-68A82EE6-8D16-40EB-BF65-FED815D3738FQ26779177-494B5A71-689A-4D8E-A338-0959C07D8771
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Multiple sclerosis
@ast
Multiple sclerosis
@en
Multiple sclerosis
@nl
type
label
Multiple sclerosis
@ast
Multiple sclerosis
@en
Multiple sclerosis
@nl
prefLabel
Multiple sclerosis
@ast
Multiple sclerosis
@en
Multiple sclerosis
@nl
P3181
P1433
P1476
Multiple sclerosis
@en
P2093
Alasdair Coles
P304
P3181
P356
10.1016/S0140-6736(08)61620-7
P407
P577
2008-10-25T00:00:00Z